US EditionInhibrx Reports Fourth Quarter and Fiscal Year 2024 Financial Results
- Inhibrx reported its financial results for fiscal year 2024, showing a net income of $1.7 billion, compared to a net loss of $241.4 million in 2023.
- Inhibrx's Phase 1 trial of ozekibart showed significant efficacy, with one complete response and three partial responses among patients treated for colorectal cancer.
- INOVIO reported a net loss of $107.3 million for fiscal year 2024, with revenues of $218,000 compared to $832,000 in 2023.
- INOVIO anticipates submitting a Biologics License Application for INO-3107 in mid-2025 after resolving device-related manufacturing issues.
97 Articles
97 Articles
Post Register
Wesdome Reports Fourth Quarter and Year-End 2024 Financial Results
TORONTO, March 19, 2025 (GLOBE NEWSWIRE) -- Wesdome Gold Mines Ltd. (TSX:WDO, OTCQX:WDOFF) (“Wesdome” or the “Company”) today announced its results for the three and twelve months ended December 31, 2024 (“Q4 2024” and “FY 2024”). Preliminary operating results for…
Cambridge Times
TILT Holdings Reports Fourth Quarter and Full Year 2024 Results
PHOENIX, March 19, 2025 (GLOBE NEWSWIRE) -- TILT Holdings Inc. (“TILT” or the “Company”) (Cboe CA: TILT) (OTCQB: TLLTF), a global provider of cannabis business solutions including inhalation technologies, cultivation, manufacturing, processing, brand development and retail, is reporting its financial…
The Berkshire Eagle
INOVIO Reports Fourth Quarter and Full Year 2024 Financial Results and Operational Highlights
Significant progress toward submitting a biologics license application (BLA) for INO-3107 as a potential treatment for recurrent respiratory papillomatosis (RRP)Resolved previously announced manufacturing issue concerning the single-use array component of the CELLECTRA device and completed drafting of all non-device BLA…
Coverage Details
Bias Distribution
- 54% of the sources are Center
To view factuality data please Upgrade to Premium
Ownership
To view ownership data please Upgrade to Vantage
